Search Medical Condition
Please enter condition
Please choose location

Doha, Qatar Clinical Trials

A listing of Doha, Qatar clinical trials actively recruiting patients volunteers.

RESULTS

Found (28) clinical trials

Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis

In the presence of infection, normal immune and physiologic responses act in concert to eradicate pathogens. When these responses are inappropriately regulated, sepsis develops. Sepsis is characterized by systemic manifestations of infection. The diagnosis is made by identifying at least 2 of the components of the systemic inflammatory response syndrome ...

Phase N/A

0.0 miles

Learn More »

DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes

The global prevalence of Type 2 Diabetes (T2D) is rapidly rising throughout most regions of the developed and developing world. In Middle East countries, particularly in the Gulf Council countries, the diabetes pandemic along with the rates of obesity have risen due to the adoption of a modern lifestyle. In ...

Phase N/A

0.0 miles

Learn More »

Next Generation DNA Sequencing in Patients With Idiopathic Male Infertility

Infertility involves about 15% of couples who attempt to conceive and the male factor accounts for about half of the cases. Idiopathic, azoospermia, or oligozoospermia, which may be genetically based, constitute a significant number of male infertility cases.In the recent years, there is increasing recognition of the genetic abnormalities as ...

Phase N/A

0.0 miles

Learn More »

Genetics of Mendelian Diseases in Qatar

There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools. These include high-throughput sequencing and genotyping along with the necessary bioinformatics analyses that ...

Phase N/A

0.0 miles

Learn More »

Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes

Diabetes is a serious health issue for the Qatari population since approximately 1/5 of the population has Type 2 Diabetes, which is 2-3 times higher than the world average. Although much of the clinical studies of diabetes often focused on microvascular phenotypes such as retinopathy and nephropathy, and macrovascular diseases ...

Phase N/A

0.0 miles

Learn More »

Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population

Diabetic nephropathy (DN) is a common vascular complication of Type 2 diabetes (T2D) that is associated with increased mortality and poor quality of life.In industrialized countries, DN ranges first among other etiologies of end-stage renal disease (ESRD).Diabetes in Qatar is a serious health issue for the Qatari population since approximately ...

Phase N/A

0.0 miles

Learn More »

Qatar Universal Diabetes Outcomes (QUDOS) Study

QUDOS aims to gain a better understanding of diabetes in primary and secondary care over a period of 24 months. A range of patients with diabetes will be sampled (including those with Type 1 diabetes as this group is under-studied in Qatar). This will be important in designing appropriate intervention ...

Phase N/A

0.0 miles

Learn More »

Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment

208 subjects (i.e., 137 per surgical group; 71 per conservative group) with TL burst fractures AOSpine classification type A3 or A4 without neurological deficit as defined in the inclusion/exclusion criteria, and with or without suspected Posterior Ligament Complex (PLC) injury (M1) from T10 to L2, will be enrolled in a ...

Phase N/A

0.0 miles

Learn More »

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

poorly controlled (HbA1c >7.5%) T2DM patients (18-75 years of age) on maximal/near maximal dose of sulfonylurea plus metformin who otherwise are healthy will be randomized to receive: 1. exenatide weekly injection (2 mg/week) 2. glargine insulin plus insulin aspart which will be titrated to maintain HbA1c <7.0%

Phase N/A

0.0 miles

Learn More »